Print  |  Close

Long-Term Follow-up Study

Active: Yes
Cancer Type: Unknown Primary NCT ID: NCT05332054
Trial Phases: Protocol IDs: LTFS (primary)
NCI-2022-06153
CB-LTSS
Eligibility: 18 Years and older, Male and Female Study Type: Other
Study Sponsor: Caribou Biosciences, Inc.
NCI Full Details: http://clinicaltrials.gov/show/NCT05332054

Summary

This is an observational, non-interventional, LTFS of investigational Caribou therapies
in patients who have participated in a parent study: a prior Caribou-sponsored clinical
study, special access program, or an IIT. The objective is to evaluate the long-term
safety, through 15 years post infusion, in patients who received IPs in a
Caribou-sponsored clinical study, special access program or IIT.

Objectives

This is an observational, non-interventional, LTFS of investigational Caribou therapies
in patients who have participated in a parent study: a prior Caribou-sponsored clinical
study, special access program, or an IIT. The objective is to evaluate the long-term
safety, through 15 years post infusion, in patients who received IPs in a
Caribou-sponsored clinical study, special access program or IIT.

Treatment Sites in Georgia

Georgia Cancer Center at Augusta University
1411 Laney Walker Boulevard
Augusta, GA 30912
www.augusta.edu/cancer/

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.